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Fc gamma receptors (FcγRs) play a major role in the regulation of humoral immune
responses. Single-nucleotide polymorphisms (SNPs) of FCGR2A and FCGR3A can
impact the expression level, IgG affinity and function of the CD32 and CD16 FcγRs in
response to their engagement by the Fc fragment of IgG. The CD16 isoform encoded
by FCGR3A [158V/V] controls the intensity of antibody-dependent cytotoxic alloimmune
responses of natural killer cells (NK) and has been identified as a susceptibility marker
predisposing patients to cardiac allograft vasculopathy after heart transplant. This
study aimed to investigate whether FCGR2A and FCGR3A polymorphisms can also
be associated with the clinical outcome of lung transplant recipients (LTRs). The SNPs
of FCGR2A ([131R/H], rs1801274) and FCGR3A ([158V/F], rs396991) were identified
in 158 LTRs and 184 Controls (CTL). The corresponding distribution of genotypic and
allelic combinations was analyzed for potential links with the development of circulating
donor-specific anti-HLA alloantibodies (DSA) detected at months 1 and 3 after lung
transplant (LTx), the occurrence of acute rejection (AR) and chronic lung allograft
dysfunction (CLAD), and the overall survival of LTRs. The FCGR3A [158V/V] genotype
was identified as an independent susceptibility factor associated with higher rates of AR
during the first trimester after LTx (HR 4.8, p < 0.0001, 95% CI 2.37–9.61), but it could
not be associated with the level of CD16- mediated NK cell activation in response to the
LTR’s DSA, whatever the MFI intensity and C1q binding profiles of the DSA evaluated.
The FCGR2A [131R/R] genotype was associated with lower CLAD-free survival of LTRs,
independently of the presence of DSA at 3 months (HR 1.8, p = 0.024, 95% CI
1.08–3.03). Our data indicate that FCGR SNPs differentially affect the clinical outcome of
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LTRs and may be of use to stratify patients at higher risk of experiencing graft rejection.
Furthermore, these data suggest that in the LTx setting, specific mechanisms of humoral
alloreactivity, which cannot be solely explained by the complement and CD16-mediated
pathogenic effects of DSA, may be involved in the development of acute and chronic
lung allograft rejection.
Keywords: Fc-gamma receptors, natural killer cells, lung transplantation, chronic lung allograft dysfunction, HLA
antibodies, allograft rejection
INTRODUCTION
Lung transplantationi (LTx) remains a challenging therapeutic
option for patients with end-stage pulmonary disease. Significant
improvement in immunosuppressive strategies has led to
decreased lung allograft loss in the early post-transplant period.
When compared to other solid organ transplantation settings,
LTx remains associated with the lowest survival rates with
a median survival of 6 years after transplant (1). Chronic
lung allograft dysfunction (CLAD) is the main cause of
chronic lung allograft rejection and is characterized by an
irreversible loss of lung function associated with a high
prevalence of complications such as bronchiolitis obliterans
syndrome (BOS) and restrictive allograft syndrome (RAS)
(2). Factors that relate to the HLA mismatch, to the graft
procedure (ischemia, unilateral or bilateral surgery) and initial
lung disease can lead to highly variable levels of recipient
immune response to the lung allograft. Inflammatory biomarkers
and antibodies, occurrence of acute cellular rejection (ACR),
infections/colonization, auto-immunity, and air pollution have
been analyzed for their potential predictive value in anticipating
development of immunological responses associated with CLAD.
Toll receptors, pro-inflammatory cytokines and non-classical
HLA molecules, i.e., HLA-G and HLA-E polymorphisms or
haplotypes, have been associated with CLAD (3–9), but the
underlying mechanisms involved in this devastating outcome of
LTx in a given recipient are still poorly understood. Antibody-
mediated rejection (ABMR) has been associated with a higher
incidence of chronic lung allograft dysfunction (CLAD) and
mortality after LTx but the specific mechanisms and histological
or immunological biomarkers that allow to define the clinical
ABMR entity still await further comprehension (10). Detection
of preexisting or development of de novo donor-specific human
leukocyte antigen (HLA) alloantibodies (DSAs) have been
extensively investigated for their potential value as biomarkers of
humoral responses that may predict adverse outcome of LTx.
Various studies suggest that the pre-transplant detection of
circulating DSA is not associated with an increased risk of
Abbreviations: HLA, Human Leukocyte Antigen; LTx, Lung Transplant;
LTRx, Lung Transplant Recipient; Abs, Antibodies; Ag, Antigen; DSA, Donor-
Specific Antibodies; BOS, Bronchiolitis Obliterans Syndrome; CLAD, Chronic
Lung Allograft Dysfunction; ADCC, Antibody dependent cell cytotoxicity; CT,
Computed Tomography; RAS, Restrictive Allograft Syndrome; ABMR, Antibody
Mediated Rejection; ACR, Acute Cellular Rejection; SAFB, Single-Antigen Flow
Beads; D, Days; M, Month; CMV, Cytomegalovirus; MFI, Mean Fluorescence
Intensity; OS, Overall Survival; DFS, Disease Free Survival; CDC, Complement-
Dependent Cytotoxicity; CF, Cystic Fibrosis.
developing CLAD or related death if prospective cross-match
testing was negative (11, 12). The pretransplant detection of
DSA and antibodies directed againd non-HLA antigens such
as angiotensin type 1 receptor (AT1R) and endothelin type A
receptor (ETAR) is reported to have a negative impact on lung
transplant outcome (13).
Early detection of de novo DSA detected at 1 month after
LTx has been significantly associated with a worse outcome (14).
Multiplex solid phase single antigen bead assay (SAFB) detection
of de novo DSAs, notably anti-HLA DQ DSA, have also been
associated with acute cellular rejection (ACR) (15) CLAD (16–
18). The presence of circulating DSA at the time of lung allograft
biopsy has been identified as a risk factor for graft loss (19).
Although there is more and more direct and indirect evidence
regarding the role of de novo DSA in CLAD occurrence, the
mechanisms that sustain the variable toxicity of these anti-HLA
antibodies to the lung allograft are still unclear. One of the well-
known cytotoxic mechanisms of DSA occurs through the IgG-
mediated activation of the complement cascade that results in
C4d deposition within the graft. C4d staining in lung allograft
biopsies is considered as a diagnosis criteria for ABMR (10, 20–
28). However, although recent evidence suggests that detection of
complement-binding DSA can be associated with lung allograft
failure (29), the predictive value of complement-binding DSA on
LTx clinical outcome remains to be firmly demonstrated.
IgG antibodies can also activate the immune system
through ligation of functional Fc gamma receptors (FcyRs).
Since these receptors are expressed by a variety of immune
cells, including B cells, natural killer cells, platelets, dendritic
cells and macrophages, FcR receptors constitute a major
checkpoint that regulates the intensity of auto- and allo-
immune responsiveness of the host in response to infectious
and humoral threats (30, 31). As infections and the immune
alloreactivity of the recipient toward the transplant remain a
leading cause of graft rejection and death during the first year
after LTx, there is a need for biomarkers that may improve
the monitoring of early humoral responses in LTRs (32–34)
and open therapeutic perspectives to dampen antibody-driven
inflammation in immunized patients (35, 36).
Polymorphisms of FcγRIIA (FCGR2A [131R/H], rs1801274)
FcγRIIIA (FCGR3A [158V/F], rs396991) genes, that respectively,
encode for the CD32 and CD16 receptors for the Fc segment
of IgG, have an impact on the level of expression and
immune function of these activating FcγRs. Various reports have
highlighted the clinical relevance of these SNPs in controlling
the host immune response to monoclonal antibody therapy.
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The presence of a histidine (H) rather than an arginine (R)
at position 131 results in higher affinity for IgG1 and IgG2.
The FCGR2A [131H/H] genotype has been associated with
higher efficacy of Rituximab-mediated B cell depletion strategies
before transplant of ABO-incompatible organs. This FCGR2A
[131H/H] SNP has also been identified as a susceptibility
marker associated with the severity of community-acquired
pneumonia (37).Genetic variation in the FCGR2A gene has also
been shown to be associated with an increased prevalence of
invasive pneumococcal diseases and respiratory infections after
LTx (38, 39), regardless of the site of pneumococcal infection
(40). Pro-inflammatory effects associated with the FCGR2A
[131R/R] genotype have also been reported as a consequence
of activating signals that result from the dynamic interactions
between CD32 and its cognate C-reactive protein (CRP) and
immunoglobulin ligands.
The clinical relevance of CD16 inflammatory pathways in
antibody-mediated rejection of kidney and heart allografts has
also been illuminated by studies that deciphered the molecular
landscape of immune and endothelial cell transcripts that
associate with ABMR lesions evaluated in allograft biopsies (41–
43). Ligation of the Fc domain of IgG has also been identified
as a mechanism that allows CD16-dependant clearance of viral
pathogens by immune NK cells (44). Recent studies suggest that
the Fc fragment of DSA can indeed exert its adverse cytotoxic
and inflammatory effects though a complement-independent
mechanism that relies on level of expression of the NK-cell
surface CD16 receptor and its affinity for the Fc fragment of
alloantibodies. The intensity of host antibody dependent cell
cytotoxicity (ADCC) is known to be conditioned by the capacity
of NK effector cells to form conjugates with antibody-coated
allogeneic cells, which is in part influenced by the FCGR3A
[158V/F] genotype (45–47). We and others have recently shown
that polymorphic variation in the FCGR3A genes is also likely to
affect the pathogenic effects of IgG alloantibodies by controlling
the level of the CD16 dependent recipient’s immunological
cytotoxic responses to allogeneic donor cells exposed to chronic
alloantibody threat (35, 48–51).
Genotypic variation in the FCGR3A receptor can thus impact
the strength of FcR-dependent ADCC responses of NK cells and
regulate their capacity to secrete inflammatory cytokines and
release CD107a/Lamp1+ cytotoxic granules containing perforin
and granzyme (50, 52, 53). The inter-individual variability in
the functional CD16 receptor-dependent engagement by the Fc
fragment of alloantibodies has been shown to condition the
intensity of antibody-dependent cellular cytotoxicity (ADCC) of
NK cells and the response to IgG immunotherapy.
The strength of FcR-mediated ADCC can also be affected by
the isotype and glycosylation status of alloantibodies. The IgG1
and IgG3 isoforms have higher affinity for the CD16 FCGR3A
[158V/V] variant when compared to FCGR3A [158F/F], thereby
spurring increased effector cell activity in response to these IgG
subclasses. We have shown that this high-affinity homozygous
FCGR3A [158V/V] genotype is an independent predictor of
cardiac allograft vasculopathy (48) and may be a clinically
relevant underlying mechanism that sustains the level of DSA-
mediated allograft injury (48–50). The recent evidence that the
NK cell infiltration of the graft can predict kidney graft failure
also sustains the clinical relevance of these NK cell mediated
mechanisms of allograft injury (54).
Considering the central contribution of polymorphisms
affecting FcγRIIA and FcγRIIIA genes and receptor function in
the individual shaping of antibody-mediated inflammatory and
cytotoxic alloimmune responses of the recipient, deciphering
the mechanisms and FcγR susceptibility profiles that may be
associated with LTx outcome is necessary to optimize risk
stratification (8).
This study thus aimed to investigate whether FcγR
polymorphisms may be linked to the pathogenic mechanisms
of DSA toxicity and be associated with adverse clinical
complications that impair patient and allograft outcome
after LTx.
MATERIALS AND METHODS
Participants and Study Design
We conducted a retrospective single-center study enrolling 158
adult patients who underwent lung transplants (LTx) at the
Marseille Lung Transplant Center between December 2006 and
December 2013. All patients from the French cohort (COLT,
Cohort in Lung Transplantation, l’Institut du Thorax, INSERM
UMR1087/CNRS UMR 6291, CNIL 911142) were recruited
in this study. All subjects gave written informed consent in
accordance with the Declaration of Helsinki. A group of 184
healthy unrelated volunteer French bone marrow donors were
also recruited to constitute a control cohort, allowing the analysis
of the FcγR genotype. Blood donations were collected in the
“Etablissement Francais du Sang,” in accordance with BSL-2
practices. A medical interview was carried out prior to blood
donation to exclude donors with medical contraindications. This
study was carried out in accordance with the French Public
Health Code (art L1221-1), approved by an institutional ethics
committee and conducted in compliance with the Good Clinical
Practice Guidelines declaration of Helsinki and Istanbul.
Post-transplant Clinical Management
All recipients received a similar standardized
immunosuppressive regimen in accordance with our
institutional protocols. Induction therapy consisted of
intravenous administration (IV) of rabbit anti-thymocyte
globulins (rATG, Pasteur Merieux, Lyon, France) given for the
first 3 post-operative days [except when daily lymphocyte count
was below 200/mm3, and when there were cytomegalovirus
(CMV) and/or EBV mismatches (i.e., seronegative recipient
and seropositive donor)] and high dose methylprednisolone (6
mg/kg/d Day 1, 2 mg/kg/d Day 2 and Day 3, and 1 mg/kg/d
thereafter). The standard triplemaintenance immunosuppressive
regimen consisted of tacrolimus (adjusted to maintain whole
blood levels varying between 12 and 14 ng/ml), mycophenolate
mofetil in 5 patients (adjusted to a white blood cell count
above 4,000 mm3), and steroids (prednisone) tapered to 0.25
mg/kg/d over the first 3 months and stopped around 12 months
after surgery.
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According to CMV recipient positive (R+) and donor
positive/recipient negative (D+/R–) status, patients
received CMV prophylaxis with IV ganciclovir switch to
oral valganciclovir.
Postoperatively, recipients received prophylactic or
preemptive anti-infection treatment (antibiotic, antiviral,
and antifungal therapies) according to their preoperative and/or
concomitant infectious status.
Recipients had regular visits to the transplant center
for clinical radiological and functional evaluation. At our
institution, surveillance transbronchial biopsies are routinely
performed at the end of the first month, or earlier if clinically
indicated. All transbronchial biopsies were graded for ACR (A
grade) and lymphocytic bronchiolitis (B grade) (LB) by lung
transplant pathologists. ACR and LB were defined, respectively,
as perivascular or peribronchial mononuclear inflammation
according to the International Society for Heart and Lung
Transplantation (ISHLT) criteria. Histologic appraisal of ACR
and LB was conducted in accordance with accepted ISHLT
standards in terms of the minimum number of biopsy samples
and exclusion of opportunistic infection (27, 28). Pulmonary
function tests (PFTs) were routinely conducted at our center on
a monthly basis for the first 12 post-operative months, at M2
intervals in the second year and at M3 intervals thereafter. The
baseline FEV1 value was calculated as the average of the 2 best
FEV1 values at least 2 measure gap. Baseline values of total lung
capacity (TLC) and FEV1/FVC were defined as the average of the
2 measurements obtained at the same time as the best 2 FEV1
measurements. Chronic lung allograft dysfunction (CLAD) was
defined according to the standardized international criteria (55).
The phenotype BOS or RAS was specified according to ISHLT
guidelines (56). The following histological patterns compatible
with AMR were also analyzed: (i) neutrophil capillaritis and (ii)
acute lung injury with or without diffuse alveolar damage and
with or without organizing pneumonia.
HLA Antibody Screening and Identification
Protocol
Recipient serum samples from 2006 to 2013 were collected
routinely prior to transplant, at the minimum when the patient
was placed on the waiting list and before the transplant procedure
(D0: Day 0) and serially after LTx (at month 1 and 3). All sera
samples obtained from the 158 recipients were further assessed
using Luminex single-antigen flow beads (SAFB) to determine
antibody specificity using Single Antigen—One Lambda reagents
(LABScreen R© Single Antigen class I or LABScreen R© Single
Antigen class II, One Lambda, Thermo Fisher Scientific, Canoga
Park, California, USA) according to the recommendations of
the manufacturers. The mean fluorescence intensity (MFI)
used the baseline formula proposed by the FusionTM v 3.2
software. All beads with a normalizedMFI threshold>1,000 were
considered positive. Since detected circulating alloantibodies
were often directed against distinct HLA class I and/or class
II antigens, the cumulative mean fluorescence intensity (cMFI)
of DSA was calculated as the sum of the MFI for each of the
individual DSAs detected. DSA were considered to be HLA
antibodies directed against donor HLA antigen. Putative HLA-
Cw and -DQA1 DSA were identified in accordance with the
conventional linkage disequilibrium that is reported between
HLA-B and HLA-C loci and between HLA-DQB1 and HLA-
DQA1 loci, as respectively, described in the French population
(57) and by supplementary extensive genotyping of HLA- genes
in the recipient. Putative HLA-DR51, -DR52 and -DR53 DSA
were determined in accordance with the linkage disequilibrium
between DRB3, DRB4, DRB5 loci and DRB1 loci of recipient.
The allelic specificities of HLA-Cw, DQA and -DR51, -DR52 and
-DR53 DSA were assigned accordingly.
C1q Detection
All patients with HLA antibodies were tested for the presence
of C1q. The binding level was determined by the C1qScreenTM
assay per manufacturer instructions (One Lambda, Thermo
Fisher Scientific, Canoga Park, California, USA). Fluorescence
intensity was measured using Luminex-based LABScanTM 100
flow analyzer. C1q specific antibody specificity and binding levels
were analyzed and determined through the FusionTM v 3.2
software. C1q MFI > 1,000 was considered positive.
FCGR2A and FCGR3A Genotyping
The detection of single nucleotide polymorphisms (SNPs)
allowed for the genotyping of FCGR3A ([158V/F], rs396991)
and FCGR2A ([131R/H], rs1801274) as described (5, 48)
using the SNAPSHOT technique. Genomic DNA was extracted
from a 200-µl whole blood sample using the QIAmp Blood
DNA Mini kit (Qiagen, Courtaboeuf, France) according to
manufacturer instructions. A previously described homemade
primer extension method (58) was used to simultaneously
analyze the SNPs of the FcγR genes. The forward and reverse
primers sequences were, respectively: FCGR3A-F 5′ TCCTAA
TAGGTTTGGCAGTG 3′ and FCGR3A-R 5′ AAATGTTCA
GAGATGCTGCT 3′, FCGR2A-F 5′ CCAGGAGGGAGAAAC
CATC 3′ and FCGR2A-R 5′ CTCTTCTCCCCTCCCTACAT
3′. The extension primers are, respectively: FCGR3A_176-F:
30T-CCTACTTCTGCAGGGGGCTT and FCGR2A_166F 57T-
CCAAAAGCCACACTCAAAGA. Data were analyzed using
GeneMapper 4.0 with specific detection parameters. Using
an in-house computer program, output files (.txt) exported
from GeneMapper 4.0 were automatically formatted into files
readable by the “Phenotype” application of the Gene[Rate]
computer tool package (http://geneva.unige.ch/generate). For
each different allele obtained, PCR products were sequenced
on both strands using the BigDye Terminator v1.1 Sequencing
Kit (Applied Biosystems) and analyzed on an automated
fluorescence-based ABI PRISM 3130 XL genetic analyzer
according tomanufacturer protocol. FcR polymorphisms at these
4 loci were analyzed for allele frequencies, or homozygous or
heterozygous allelic combination of FcγR alleles defining the
corresponding genotype.
HLA Genotyping
Recipients and deceased donors were genotyped for low
resolution HLA-A, -B, -DRB1, and -DQB1 loci by LABType R©
SSO (One Lambda, Thermo Fisher Scientific, Canoga Park,
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California, USA) according to the manufacturer’s specifications
and the retrieved output was analyzed for allele identification
using HLA FusionTM v 1.2.1. Software (One Lambda, Thermo
Fisher Scientific, Canoga Park, California, USA).
Phenotypic Analysis of
Antibody-Dependent NK Cell Activation
Evaluation of the CD16-dependent alloreactive potential of DSA
was assessed using the previously described NK cell humoral
activation test (NK-CHAT) (50). The level of serum-induced
CD16 engagement and the degranulating potential of NK
cells was assessed by flow cytometry analysis of the level of
CD16 cell surface expression within the CD3−CD56+ NK cell
compartment, gated within PBMC effector cells after exposure to
target B cells that had been precoated in the presence of LTRs
or control sera. Effector cells used in the standardized assay
were prepared from a healthy donor displaying the FCGR3A
[158V/V] encoding the high-affinity CD16 variant. The HLA
typing of the two B cell lines used as targets were A2/A2,
B44/B56, Cw1/Cw5, DR1/DR4, DR53, DQ5/DQ7 and A3/A3
B7/B35, Cw4/Cw5, DR10/DR15, DR51, DQ5/DQ6). Sera were
selected for the presence of DSA recognizing a limited set of
HLA antigens expressed by EBV target cell lines. Briefly, 500,000
target B cells (B-EBV cell lines expressing the cognate DSA target
alloantigens detected in LTR) were incubated with control (CTL)
unsensitized human male AB serum (Lonza) to block FcR, then
rinsed and incubated for 15min in the presence of 50% LTR
serum [or CTL serum supplemented or not with 10 γg/ml of
Rituximab IgG (positive control)] and then rinsed to remove
unbound antibodies. Incubation of effector PBMC and pre-
coated allogeneic B-EBV cell targets (1:1 ratio) was performed for
3 h at 37◦C in presence of GolgiStop (Becton Dickinson 554724)
and CD107-PC5 (Becton Dickinson 555802). Cells were then
washed and labeled with CD3-ECD (Beckman Coulter A07748),
CD16-PE (Beckman Coulter A07766), CD56-PC7 (Beckman
Coulter A21692) for 15min at room temperature protected from
light. After 1 wash step, cells were resuspended in 500 µl PBS 2%
SVF. Data acquisition and analysis was performed on a Beckman
Coulter Navios cytometer. The mean fluorescence intensity
of CD16 and percent of NK cells expressing Lamp1/CD107a
expression was analyzed within the CD3-CD56+ NK cell subset.
The NK-CHAT CD16 down regulation index (CD16DRI) was
evaluated as a ratio between CD16 MFI measured on NK
cells incubated with target cells in presence of effector cell
autologous CTL serum/CD16 MFI of NK cells incubated with
target cells and recipient serum to be tested. CD16DRI = (MFI
CD16 control serum)/(MFI CD16 test serum). Alternatively,
when serum at time of LTx was available for the assay, the
baseline CD16 expression was evaluated in reference to the DSA
negative serum collected at time of LTx. Sera containing HLA-
DQ7 DSA obtained from kidney transplant recipients (KTR)
with antibody-mediated rejection (ABMR) at time of diagnosis,
previously described to induce high levels of CD16-dependent
NK cell alloreactivity, were introduced as positive controls of
the experiments, indexing the CD16 down regulation induced by
LTx sera.
Statistical Analyses
Variables used to perform univariate and multivariable analyses
included preoperative donor variables (donor age, sex, CMV
status, HLA typing), preoperative donor–recipient matching
parameters (age, sex, CMV status, andHLAmismatch), operative
variables such as ischemia time, type of procedure (single vs.
bilateral LTx) and preoperative and post-operative recipient
variables (initial lung disease, HLA typing, pre- and post-
transplant immunization status, occurrence of AR BOS, RAS,
CLAD, or infectious bacterial episodes occurring during the
first year post-transplant), and notably during the early post-Tx
period at months 1 (M1) and 3 (M3) after LTx (Table 1).
Continuous variables were presented as median values and
25–75 interquartile ranges or mean ± sd according to their
distribution evaluated using the Agostino & Pearson omnibus
normality test performed using GraphPad Prism version 5.00
for Windows (GraphPad Software, La Jolla, California, USA).
Categorical variables were presented as percentages. Fisher’s exact
test and the chi-square test were used to compare categorical data
and t-tests or Mann Whitney tests were used for the comparison
of continuous variables.
The primary endpoints of this study were overall survival (OS)
and disease/CLAD-free survival (DFS). OS was defined as the
interval between the date of transplant and the last follow-up visit
or death. DFS was defined as the time interval from transplant
to the first event: either the graft failure or diagnosis of acute
rejection or CLAD in living recipients, or the death of the patient.
The Kaplan-Meier method was used to estimate overall survival
and rejection-free survival. The log-rank test was used to assess
the univariate effects on OS and DFS. For all analyses, a 2-sided
p < 0.05 was considered statistically significant. Variables with a
p< 0.2 were also considered to construct multivariate regression
models. Multivariate analyses were performed using Fine and
Gray’s proportional hazards regression model. All analyses were
performed using IBM SPSS 15.0 software (SPSS Inc., Chicago,
IL) and the cmprsk package (developed by Gray, June 2001) on
R2.3.0 software (http://www.R-project.org).
RESULTS
Characteristics of the LTR Cohort
The demographic characteristics and clinical features of the 158
adult LTRs (median age: 42 years, 75 females and 83 males) are
summarized in Table 1. Patients received a first LTx for cystic
fibrosis (37%), emphysema (29%), pulmonary fibrosis (22%), or
another diagnosis (12%). The median follow-up time was 38
months after LTx. Median survival time of the 94 patients who
were alive at time of follow-up was 4.2 years. Sixty-four patients
(40.5%) died during the study follow-up (median time before
death 12.6 months, 25–75 interquartile range: 1.8–35.5 years)
and 5 patients experienced CLAD-associated graft failure with
indication of a second lung transplant or death. Among deceased
patients, 32 patients died during the first year post-LTx, among
which 12 patients died during the first month post-LTx and 9
between the first and third months post-LTx. Acute rejection
diagnosis was confirmed in the lung transplant biopsy of 53
patients (36%), the first rejection episode occurring before the
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TABLE 1 | Demographic and Clinical characteristics of LTRs.
Recipient, n 158
Recipient age at LTx (years), median(25–75) 42 (30–54)
Recipient Age ≥ 50, n (%) 54 (34)
Donor Age, median (25–75) 43 (29–54)
Male Gender, n (%) 83 (53)
Native Lung Disease
Cystic Fibrosis, n (%) 59 (37)
Fibrosis, n (%) 35 (22)
Emphysema, n (%) 46 (29)
Other, n (%) 18 (12)
Transplantation type
Bilateral LTx, n (%) 118 (74)
Single LTx, n (%) 36 (24)
Other, n (%) 4 (2)
CMV Risk
CMV R- (%) 50
CMV Mismatch D+R- (%) 21
Immunization Status
HLA Mismatch, median (25–75) 7 (6–7)
DSA M1, n 49
MFI DSAM1, median (25–75) 13,000 (5,500–18,750)
DSA M3, n 27
MFI DSA M3, median (25–75) 7,100 (3,500–13,500)
M1 DSA persisting at M3, n 21
C1q DSAM1, n 20
C1q DSAM3, n 7
Bacterial Infections
M1, n 20
M3, n 11
First year, n 35
Transplant Outcome
Time follow up post-LTx (months), median (25–75) 38.5 (23–62)
Rejection events
Biopsy proven Acute rejection Day 0-M3, n (%) 41 (28)
Biopsy proven Acute rejection first year, n (%) 53 (35)
Time before Acute Rejection event (Days), median
(25–75)
42 (22–179)
CLAD, n 40 (25)
Time before CLAD (months), median (25–75) 22 (13–32)
BOS, n (%) 35 (22)
RAS, n (%) 5 (3)
Allograft and Patients’ Survival
CLAD- or Graft failure-free Survival, n (%) 71 (45)
Death, n (%) 64 (40)
Time before Death (months), median (25–75) 13 (1.8–35)
Death or Graft failure with 2nd LTx, n (%) 68 (43)
Data are presented as a number and %, or median (25–75 Interquartile ranges). BOS,
Bronchiolitis obliterans syndrome; RAS, restrictive allograft syndrome; CLAD, chronic lung
allograft dysfunction; M1 and M3, month 1 and 3 post-LTx.
third month in 41 LTRs (occurring before the fourth month in
24 LTRs and during the third month and the twelfth month
post-LTx in 11 LTRs). The occurrence of acute rejection could
be associated with the presence of DSA in 49% of these patients
(n = 20). During the study period, 40 LTRs (25%) developed
CLAD, of which 35 (87%) had BOS and 5 (12%) had RAS.
Seventeen of the patients with a CLAD diagnosis did not survive
and 5 were considered for a second transplant procedure. CLAD-
free survival of the graft was observed in 71 patients (45%)
with a median disease-free survival time of 4.2 years (25–75
percentile: 3.1–5.8).
Distribution of FCGR3A and FCGR2A
Polymorphisms
Genotyping of the FCGR2A and FCGR3A polymorphisms was
performed in 158 LTRs and analyzed in reference to a control
cohort of 184 healthy donors (CTLs) (Figure 1). The FCGR2A-
H allele was detected in 75.3% of LTRs and 83.1% of CTLs
(p = 0.0734) while the -R allele was detected in 67.7% of LTRs
and in 76% of CTLs (p = 0.0851). Although the distribution of
FCGR2A [131R/R] and FCGR2A [131H/H] was not significantly
altered in LTRs, the frequency of FCGR2A [131H/R] was found
to be significantly lower in LTRs analyzed in reference to CTLs
(chi-square p = 0.0028). The distribution of FCGR3A alleles did
not significantly differ between patients and controls; presence
of the -F allele was detected in 81% of LTRs and in 83.7% of
CTLs while the -V allele distribution was in 64.6% of LTRs
and in 68.5% in CTLs. The genotype frequencies of the various
genotype combinations resulting from analysis of these SNPs
in the LTR and CTL cohorts are illustrated in Figure 1. The
frequency of the FCGR3A [158F/F] genotype was positively
correlated with the FCGR2A [131R/R] genotype in CTLs and in
LTRs (p = 0.008 and p < 0.0001, respectively). Presence of the
FCGR2A [131R/R] was thus significantly associated with lower
rates of patients with the FCGR3A [158V/V] good responder
genotypes in LTRs (p = 0.038), but this inverse correlation did
not reach significance in the control cohort (Table 2). Analysis of
the groups stratified according for FCGR SNPs did not reveal any
significant difference regarding the age of the LTR and type of
underlying initial lung disease. The FCGR2A [131H/R] SNP with
was found to be associated with recipient gender (p= 0.029). The
FCGR2A [131H/H] genotype was observed to be significantly
more common in women LTRs (32 out of 51, p= 0.008).
DSA Immunization During the First 3
Months Following Lung Transplant Is
Associated With FCGR Polymorphism
During the first 3 months post-transplant, 55 patients developed
de novo circulating DSA. During the first month post-LTx (M1),
DSA developed in 49 LTRs (12 HLA class I, 20 HLA class II, and
17 HLA class I and II). The median MFI of DSA detected at M1
was 7,000 for HLA Class I DSA and 12,100 for HLA Class II
DSA and 12 patients (8%) exhibited high cMFI values of DSA
(over the 18,750 threshold corresponding to the 75 percentile
value observed for MFI analyzed at M1) (Table 1). Circulating
DSA could be detected in 27 LTRs analyzed at month 3 (M3)
post-LTx (11 HLA class I, 13 HLA class II and 3 HLA class I and
II) (Figure 2). The development of de novo DSA was observed at
M3 in 6 LTRs with no detectable DSA at M1 (4 HLA class I, 1
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FIGURE 1 | Distribution of FCGR3A and FCGR2A genotypes in LTRs and CTLs. The proportion of the FCGR2A (left Panel, A) and FCGR3A (right panel, B) genotypes
resulting from the SNP allelic combination were analyzed in a cohort of 158 LTRs and 184 CTLs recruited in southern France.
TABLE 2 | Association between the FCGR2A [131R/R] and FCGR3A [158V/F] genotypes observed in LTRs and CTLs.
FCGR2A genotype LTR
HH
n = 51
HR
n = 68
RR
n = 39
p-value FCGR2A-RR vs.
FCGR3A
FCGR3A genotype FF, n = 56 8 24 24 p < 0.001
VF, n = 72 30 30 12 p = 0.032
VV, n = 30 13 14 3 p = 0.038
FCGR2A genotype CTL
HH
n = 44
HR
n = 109
RR
n= 31
p-value FCGR2A-RR vs.
FCGR3A
FCGR3A genotype FF, n = 58 8 34 16 P = 0.008
VF, n = 96 24 59 13 p = 0.211
VV, n = 30 12 16 2 p = 0.103
HLA class II and 1 HLA Class I and Class II). The median MFI
values of DSA detected atM1 and atM3were, respectively, 13,000
and 7,100 (Table 1, Figure 2). DSA detected at M1 persisted
at M3 in 21 LTRs (44% of DSA-positive MTR at M1) and 4
of these M3 DSA were also detectable 1 year post-transplant.
HLA-DQ DSA were the only HLA class II persisting at M3. The
median cMFI level of DSA detected at M1 and persisting at M3
(14,600, 25–75 percentile, 7,000–23,250) could not be linked to
their persistence at M3 and did not significantly differ from the
cMFI of DSA observed at M1 but undetectable at M3 (median
MFI: 12,200, 25–75 percentile 4,000–16,000). Circulating DSA
directed against DQ specificities were detected in 33 LTRs at M1
(median DQ-DSA MFI: 12,000 25–75 percentile 7,600–14,500)
and in 14 LTRs at M3 (median 12,000, 5,000–15,850, 11 HLA-
DQ DSA detected at M1 persist at M3 while 3 of the 14 HLA-DQ
DSA detected at M3 were de novo DSA). C1q Binding DSA at
M1 were detected in 20 LTRs (2 HLA class I, 15 HLA class II,
and 3 HLA class I and II) with a median cMFI of C1q-binding
DSA detected at M1 of 23,000 (25–75 percentile 6,300–30,000).
Seven of the 27 DSA detected at M3 were found to bind C1q
(1 HLA class I, 5 class II HLA DSA and 1 HLA class I and
class II), with a median cMFI of 17,150 (25–75 percentile 7,000–
31,000). All C1q binding DSA detected at M3 were also detected
at M1.
The FCGR2A [131R/R] genotype was also to found to correlate
with the detection of circulating DSA at M3 (p = 0.011) and
notably to the development of de novo DSA between the first
and second months post-transplant (4 out of the 6 de novo DSA
detected at M3 were genotyped as FCGR2A [131R/R], p= 0.017).
FCGR3A [158V/V] tends to be inversely associated with the
persistence of DSA at M3 (p= 0.07, Table 3), as only 1 out of the
21 patients with persistent DSA at M3 was genotyped as FCGR3A
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FIGURE 2 | Study flow chart analysis of the detection by single antigen flow bead Luminex Assay of de novo DSA and C1q binding activity of DSA at M1 and at M3
post-LTx.
TABLE 3 | Patients immunization characteristics according to the FCGR2A and FCGR3A genotypes.
FCGR2A FCGR3A
HH/RH RR p-value FF/VF VV p-value
n = 158 119 39 128 30
DSA M1, n = 49 33 16 0.161t 40 9 0.926, ns
Median MFI DSA M1 13,000 13,500 0.639, ns 12,500 13,800 0.477, ns
C1q DSA M1, n = 24 18 6 0.919, ns 19 5 0.869, ns
DSA M3, n = 27 15 12 0.011 26 1 0.024
DQ DSA M3, n = 14 7 7 0.022 13 1 0.225, ns
M1 DSA persisting at M3, n = 21 13 8 0.146t 20 1 0.07t
Median MFI DSA M3 6,300 9,500 0.494, ns 7,500 4,500 NA
C1q DSA M3, n = 7 5 2 0.840, ns 7 0 0.187t
Continuous variables are expressed asmedian (25–75 percentile ranges). p-values of the statistical tests comparing groups (Chi-2 or non-parametric Mann-Whitney test) were considered
as significant when p-values were <0.05, tendency (t ) when p > 0.05 and <0.2 and non-significant (ns) when p > 0.2 or NA when non-applicable. M1 and M3, month 1 and 3 post-LTx.
[158V/V]. The FCGR3A-F allele was significantly associated with
the detection of circulating DSA at M3 (26 out of 27 LTRs with
detectable circulating DSA atM3were positive for the FCGR3A-F
allele, p= 0.024) (Table 3).
FcGR3A and FcGR2A Polymorphisms Are
Differentially Associated With Acute and
Chronic Lung Allograft Rejection
The FCGR3A [158V/V] was also identified as a susceptibility
genotype associated with a higher risk of acute rejection
(log rank test for equality of survivor functions p = 0.0009,
Figure 3A). Multivariate Cox regression analysis also
revealed that the susceptibility conferred by the FCGR3A
[158V/V] genotype (OR 4.8, p < 0.0001, 95% CI 2.375–
9.607) was independent from the development of DSA
at M3 and their C1q binding activity. FCGR2A [131R/H]
was not observed to affect the rate of acute rejection. The
FCGR2A [131R/R] genotype was instead associated with the
detection of DSA occurring in the absence of acute rejection
(p= 0.029).
The DSA immunization status of the patient evaluated during
the first year post- LTx could not be associated with CLAD.
Although the number of observations was small, 4 of the 5 LTRs
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FIGURE 3 | Analysis of the influence of Fc-gamma Receptor polymorphisms on Rejection Free survival. (A) Impact of FCGR3A genotype on freedom from acute lung
rejection. Kaplan–Meir Survival analysis links the FCGR3A [158V/V] (solid line, n = 20) to lower acute-rejection-free survival after 3 months post-LTx in LTRs, when
compared with the FCGR3A [158V/F] and FCGR3A [158F/F] group (dashed line, n = 81). LTRs with the FCGR3A [158V/V] show an increased rate of acute rejection
events occurring during the first 3 months post-LTx. (B) Impact of FCGR2A genotype on CLAD free survival. Kaplan–Meir Survival analysis links the FCGR2A [131R/R]
(solid line, n = 39) to a lower CLAD-free survival rate in LTRs over time or study follow-up (years, x axis), when compared with the FCGR2A [131H/H] and FCGR2A
[131R/H] group (dashed line, n = 119).
who developed RAS-associated CLAD were homozygous for the
FCGR3A–FF allele (p = 0.034). While the FCGR3A [158V/F]
could not be significantly associated with the risk of CLAD,
FCGR2A [131R/R] was identified as a susceptibility marker
associated with lower CLAD-free survival of LTRs (n = 87,
logrank test for equality of survivor functions p = 0.0123,
Figure 3B). Multivariate Cox regression models adjusting co-
variables identified using univariate analysis further identified
FCGR2A [131R/R] as an independent susceptibility marker
associated with CLAD (OR 2.2; p = 0.022, 95CI 1.126–4.435)
(Table 4). Multivariate Cox analysis further showed that the
FCGR2A [131R/R] genotype is significantly associated with the
enhanced risk of developing a composite LTx adverse outcomes
(CLAD, graft failure or death), independently of other factors
such as detection of DSA at M3 or native emphysema lung
disease (Table 4).
LTx DSAs Have No Major Impact on
CD16-Dependent NK Cell Cytotoxic
Activation
Considering our previous finding that identifies the potential
value of FCGR3A [158V/F] in predicting cardiac allograft
vasculopathy (48), we further investigated whether the presence
of association of acute rejection events with high affinity FCGR3A
[158V/V] genotype could be associated with the DSA-mediated
pathogenic effects that promote acute rejection mechanisms of
lung allograft. Using the NK-cellular humoral activation test
(NK-CHAT), previously designed to index the level of DSA-
mediated engagement of CD16 and unravel potential ADCC-
driven pathogenic effects of circulating DSA (41), we therefore
aimed to investigate whether circulating DSA detected at M1
or M3 in LTRs have the potential to stimulate NK cell
alloreactivity. Evaluation of the DSA-induced down regulation
of NK cell CD16 expression (CD16 Down Regulation Index or
CD16DRI) was performed in a standardized NK-CHAT assay
analyzing alloreactivity of NK cells toward serum-coated CD20+
B lymphocytes expressing the cognate HLA target alloantigen,
using 23 serum samples obtained from 20 distinct LTRs (Table 5).
Thirteen sera were collected at M1 and ten at M3. Four sera had
detectable DSA that persisted at M3. Seven DSA at M1 and Four
DSA at M3 were C1q positive.
Surprisingly, the CD16DRI values induced by the DSA+ LTx
sera were very low when compared to those obtained in response
to Rituximab. These CD16 DRI values could not be associated
with the intensity of DSA MFI and C1q binding activity of
DSA. Furthermore, the CD16DRI of LTRs (LTR 17, 18, and 20)
with HLA DQ7 DSA were lower than those obtained of ABMR
kidney transplant recipients (KTR) withHLADQ7DSA andwith
similar MFI (Figure 4).
In contrast to the results previously observed in the kidney and
heart transplant setting, the association of the FCGR3A [158V/V]
genotype with acute rejection appears to be independent of
the presence of circulating DSA and the DSA MFI levels. In
contrast to the KTR serum, NK-CHAT evaluation of the serum
of immunized LTRs did not reveal significant alloreactive DSA
toxicity and did not allow for determination of their pathogenic
potential in eliciting CD16 and NK-cell cytotoxic activation.
FCGR2A Polymorphism Impacts Patients
and Allograft Survival
Occurrence of acute and chronic events or infectious episodes
was not shown to have a major impact on overall survival in the
analyzed cohort.
Early development of DSA that persist at M3 (n = 21) were
associated with lower graft or patient survival rates (p = 0.002)
and were associated with the presence of the low-affinity F allelic
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TABLE 4 | Univariate analysis and multivariate Cox regression analysis of risk factors associated with acute or chronic rejection events.
Risk covariables Univariate
analysis p-value
Hazard ratio Std. Err. z P > z (95% Conf.interval)
Acute Rejection in the first 3 months post-LTx, n= 41
FCGR3A [158 V/V] 0.003 4.8 1.70 4.39 <0.0001 2.375 – 9.607
Native Lung Disease Emphysema 0.037 0.4 0.18 −2.05 0.040 0.173 – 0.961
M3 C1q Binding DSA 0.009 4.4 2.87 2.28 0.023 1.231 – 15.789
Single lung Tx 0.091 2.6 0.96 2.56 0.010 1.251 – 5.352
FCGR3A [158 V/F] 0.003 4.4 1.54 4.29 <0.0001 2.247 – 8.761
Native Lung Disease Emphysema 0.037 0.4 0.17 −2.17 0.03 0.161 – 0.909
M3 DSA+ Ns (p = 0.251) 3.1 1.27 2.82 0.005 1.417 – 6.917
Single lung Tx 0.091 2.9 1.12 2.89 0.004 1.419 – 6.243
CLAD, n= 40
FCGR2A [131R/R] 0.185 2.23 0.781 2.3 0.022 1.126 – 4.435
Native Lung Disease Emphysema 0.177 2.65 0.900 2.86 0.004 1.360 – 5.157
Recipient Gender: Female 0.142 1.62 0.531 1.47 0.141 0.852 – 3.080
Acute Rejection 1st Year 0.050 1.93 0.621 2.03 0.042 1.024 – 3.625
Composite adverse outcome: CLAD, graft loss or death n = 87
FCGR2A [131R/R] 0.185t 1.8 0.475 2.3 0.024 1.080 – 3.028
Native Lung Disease Emphysema 0.177 2.1 0.514 2.95 0.003 1.279 – 3.439
M3 DSA 0.075 1.9 0.557 2.44 0.015 1.145 – 3.080
Covariables (risk covariables) used to explain the Lung transplant outcome primary variable (Acute Rejection, CLAD or adverse composite outcome that includes CLAD or Graft loss or
death) are listed on the left column. The bold text refers to covariables that retained independent significant p-values in multivariate cox regression models.
variant of CD16. Persistence of DSA at M3 was thus lower in
FCGR3A [158V/V] LTRs (p = 0.029). Other parameters such
as high MFI DSA detected at M1 (>18,750 MFI, 75 percentile
value of DSA MFI at M1 post-LTx, p = 0.109) or FCRGR2A
[131R/R] (p = 0.052) tended to be associated with the risk of
death. While the FCGR3A genotype could not be associated to
overall survival, the FCRGR2A [131R/R] genotype was identified
as a risk factor associated with the composite adverse outcome
combining graft failure or patient death (n= 68, log rank test for
equality of survivor functions p= 0.0417, Figure 5). Multivariate
analysis of variables associated with death from all causes after
LTx (n = 64, 40.5% of the LTR cohort) retained initial diseases
other than cystic fibrosis (p = 0.048) DSA with MFI values > to
the 75 percentile 18,750 MFI value for DSA detected at M1
as significant risk factors (Table 6). The FCRGR2A [131R/R]
genotype was shown to be an independent factor associated
with lower overall survival of LTRs using multivariate logistic
Cox regression models (HR: 1.8, p = 0.047 95% CI: 1.008–
3.121, Table 6).
DISCUSSION
FcγR constitute amajormarker of immune activation in response
to infections, antibodies and CRP inflammatory ligands. Recent
studies suggest that the engagement of FcR by the Fc fragment
of alloantibodies can influence the cytotoxic activation level of
NK cells toward the heart or kidney allograft. This study aimed
to investigate whether the combined evaluation of FCGR3A
[158F/V] and FCGR2A [131H/R] SNPs and biomarkers that
index the level of CD16-dependent ADCC of NK cells might
also be relevant to stratify patients at higher risk of lung
allograft failure.
Our results show evidence that the FCGR3A [158V/V]
genotype can be identified as a genetic marker that predisposes
LTRs to acute rejection, independently of their DSA
immunization status. Fifteen out of thirty patients with the
FCGR3A [158V/V] genotype indeed developed acute rejection
during the first trimester. Since this profile has been associated
with higher NK cell responsiveness, we further investigated
how it may relate to the NK cell mediated cytotoxic effects of
DSA toward the lung allograft. Various studies have shown that
the detection of circulating DSA with an ability to ligate the
C1q component and activate the complement cascade can be
associated with a greater risk of acute rejection and allograft loss
after heart or kidney transplant. These complement-dependent
mechanisms of DSA-mediated cytotoxic effects have also been
recently documented in the lung transplant setting (19, 20).
As previously reported (29), all C1q DSA detected at M3
were directed toward donor HLA-DQ alloantigens and C1q
positive were shown to be significantly associated with acute
rejection in the study cohort. A limitation of our study is
the lack of elements allowing the distinction of cellular acute
rejection (ACR) from ABMR. Endothelial deposition of C4d
and microvascular inflammation were shown to be reliable
markers of ABMR in renal and cardiac allografts, but the clinical
relevance of C4d staining within lung allograft biopsies still
remains controversial for lungs. These diagnostic criteria for
ABMR were not always available on a routine basis at the time of
evaluation until the Banff nomenclature released more accurate
histologic features that characterize lung allograft grafts biopsies
of DSA-positive LTRs.
Frontiers in Immunology | www.frontiersin.org 10 June 2019 | Volume 10 | Article 1208
Paul et al. FcGR Polymorphisms and Lung Transplantation
TABLE 5 | NK-CHAT: Evaluation of DSA reactivity toward B cell targets expressed in sera collected from LTR and KTR, used as positive controls for NK-CHAT.
LTR Serum
Time
post-LTx
DSA HLA
class I/II
MFI DSA MFI C1q DSA Serum induced
CD107 up regulation
(CD107URI)
Serum induced CD16
down regulation
index (CD16DRI)
CLAD AR Death
LTR 1 M1 Class I A3:8,500
B7:8,500
A3:14,000
B7: > 15,000
1 1 na 1 1
LTR 2 M1 Class I A2:7,000
B44:3,000
A2: 3,000
B44: 10,000
1 1 1 1 0
LTR 3 M1 Class I A2: 3,200 Negative 1 1 1 1 0
LTR 4 M1 Class I A3: 2,300 Negative 1 1 0 0 0
LTR 5 M3 Class I B7: 3,000 Negative 1.6 1 0 1 0
LTR 6 M1 Class I and II A2: 3,500
DQ7: 13,000
DQ7: 10,000 0.4 1 0 0 0
M3 Class II DQ7: 9,000 Negative 0.5 1 0 0 0
LTR 7 M1 Class II DQ2:10,000
DR53:3,000
Negative 3.3 1.2 na 0 1
LTR 8 M1 Class II DQ5: 9,500 Negative 1.6 1 1 1 1
LTR 9 M1 Class II DQ6: 10,000 Negative 1.4 1.2 0 0 0
LTR 10 M1 Class II DQ7 > 15,000 DQ7 > 15,000 0.9 1.3 0 0 0
LTR 11 M1 Class II DQ7:11,000
DQ9:4,000
DQ7:11,500
DQ9:11,500
0.9 1 1 0 1
LTR 12 M1 Class II DQ7: 13,000 Negative 1.4 1.1 0 0 0
LTR 13 M3 Class II DQ5: 14,000 DQ5: 9,000 0.9 1.4 0 0 0
LTR 14 M3 Class II DQ5: 13,000 Negative <1 <1 na 0 1
LTR 15 M3 Class II DQ5 4,500 Negative <1 <1 0 0 0
LTR 16 M3 Class II DR53: 3,000 Negative 1 1 0 0 0
LTR 17 M3 DQ7: 13,400 DQ7 11,000 1 1
LTR 18 M3 Class II DQ7: 16,000 DQ7, 14,000 3 2.1 na 0 1
LTR 19 M1 Class II DQ5:7,500
DQ6:6,000
DQ5: 7,000
DQ6: 6,500
1.2 <1 0 1 0
M3 Class II DQ5: 3,500 Negative <1 <1
LTR 20 M1 Class II DQ7: 9,000 DQ7: 6,000 1.5 1.9 0 0 0
M3 Class II DQ7: 12,500 DQ7: 9,000 1.4 1.9
KTR 1 ABMR At time of
ABMR
diagnoss
Class II DQ7: 9,000 nt 6.5 29 na na na
KTR 2 ABMR Class II DQ7: 13,000 nt 7 42 na na na
AR, acute rejection; na, not applicable; nt, non-tested.
However, the association between the FCGR3A [158V/V]
genotype and presence of circulating DSA at M1 or at M3 did
not appear to confer a higher risk of acute rejection, whatever
their MFI and their C1q binding activity status, thus suggesting
that the graft damage associated with the FCGR3A [158V/V]
genotype is independent from DSA immunization status. This
finding was unexpected, as we have previously shown that the
intensity of antibody-dependent CD16 activation of NK cells,
indexed by the non-invasive NK-CHAT, is significantly enhanced
in recipients that bear the FCGR3A [158V/V] genotype and
constitute a relevant cytotoxic mechanism sustaining toxic effects
of DSA and allograft vasculopathy (48, 50). In contrast, NK-
CHAT evaluation of DSA from LTRs actually shows evidence that
the engagement of CD16 by LTx DSA is low when analyzed in
reference to anti-HLA class II DSA that are found in the serum
of kidney transplant recipients at time of ABMR diagnosis and
that exhibit comparable HLA-DQ7 specificities and MFI values.
This low potential of LTx DSA to induce CD16-mediated NK
cell activation appears to be independent of their C1q binding
activity and could not be associated with adverse outcome of
LTx in the present study. As CD16 exhibits higher affinity for
IgG1 and IgG3 alloantibodies, this failure of DSA to engage
CD16 mediated cytotoxic functions may be due to the IgG2
and/or IgG4 isotypes of DSA, which have been shown to exhibit
lower affinity for CD16. This finding may also indicate that the
glycosylation pattern of IgG1 DSA interferes with the FcγRs-
mediated recognition of the Fc fragment of IgG by immune
cells or complement factors. These hypotheses are supported
by the observation that only 30% of circulating DSA detected
at M1 and at M3 were found to bind C1q in this study
cohort and by previous findings that report high IgG4 levels in
patients with cystic fibrosis lung disease (59). These data suggest
that, in contrast to previous findings, the FCGR3A [158V/V]
susceptibility genotype does not appear as a major mechanism of
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FIGURE 4 | Representative illustration of the NK-Cellular Humoral test (NK-CHAT) used to evaluate serum- and DSA- induced NK cell activation toward B cell lines
expressing cognate HLA class I or HLA-DQ7 donor-specific allo-antigens. (A) PBMC effectors obtained from FCGR3A [158 V/V] CTL were exposed to B-EBV cell
lines previously coated with DSA-negative serum. This allowed for evaluation of the baseline expression level of CD16 expression (CD16MFI) within the
CD3-CD56+CD16+ NK cell compartment when PBMC were exposed to B cell targets. As a positive control indexing the level of IgG-induced CD16 down regulation
(CD16DRI), the same B-EBV cell lines were coated in the presence of 10γ/ml Rituximab (anti CD20 IgG) prior to exposure to the effector PBMC. This allowed for
calculation of the CD16 down regulation index (CD16DRI: baseline CD16MFI NK cells exposed to B cells coated with CTL DSA-negative serum/CD16 MFI of NK cells
exposed to the same B targets pre-coated in presence of Rituximab). In this context, CD16DRI in response to Rituximab = 19, i.e., 90/4.8. (B) The CD16 DRI of NK
cells was evaluated in response to the serum collected at M1 in one LTR (LTR 1, Table 5) with detectable levels of DSA recognizing the HLA-A3 and -B7 expressed on
the B cell targets. Non-immunized serum (DSA-negative) collected from LTR 1 at time of LTx (D0) was used as the reference baseline CD16 MFI value to calculate the
CD16DRI. Despite a cumulative MFI of DSA >17,000, DSA detected at M1 in LTR1 failed to induce CD16-dependent NK cell alloreactivity (CD16DRI = 1). (C) The
CD16 DRI of NK cells was evaluated in response to the serum collected at time of ABMR diagnosis in one kidney transplant recipients (KTR 1, Table 5) with
detectable levels of DSA recognizing the HLA-DQ7 (MFI: 13,000) expressed on the B cell targets. The CD16DRI of KTR1 (CD16DRI: 45) was greater than that
observed in response to the Rituximab (CD16DRI:19, A). (D) The CD16 DRI of NK cells was evaluated in response to the serum collected at time of ABMR diagnosis
in a second KTR (KTR 2, Table 5) with detectable levels of DSA recognizing the HLA-DQ7 (MFI: 9,000) expressed on the B cell targets. The CD16DRI of KTR1
(CD16DRI: 30) was greater than that observed in response to the Rituximab (CD16DRI:19, A). (E) The CD16 DRI of NK cells was evaluated in response to the serum
collected at M3 (time of acute rejection) in a second LTR (LTR 17, Table 5) with detectable levels of DSA recognizing the HLA- DQ7 (MFI: 13,400) expressed on the B
cell targets. Non-immunized serum (DSA-negative) collected from LTR 17 at D0 was used as the reference baseline CD16 MFI value to calculate the CD16DRI
(CD16DRI = 1). The MFI DSA of LTR 17 (MFI: 13,400) was similar to the MFI DSA of ABMR KTR 1 serum as illustrated in (C). (F) The CD16 DRI of NK cells was
evaluated in response to the serum collected at M3 (time of acute rejection) in a third LTR (LTR 20, Table 5) with detectable levels of DSA recognizing the HLA- DQ7
(MFI DSA: 9,000) expressed on the B cell targets. The DSA-negative serum of LTR 20 collected at D0 was used as a baseline CD16 MFI value to calculate the
CD16DRI (CD16DRI = 1.9). The MFI DSA of LTR 20 (MFI: 9,000) was similar to the MFI DSA of ABMR KTR 2 serum evaluated in (D).
DSA-mediated lung allograft injury. CD16-dependent activation
of NK cells in FCGR3A [158V/V] individuals that develop
acute rejection may nevertheless be mediated by allo- or auto-
antibodies that target non-HLA antigens andmay not be revealed
in the standardized NK-CHAT assay revealing CD16 cellular
activation toward B lymphocyte cell targets. Several reports have
indeed described ABMR lesions of the graft that occur in the
absence of detectable levels of circulating DSA in the serum
of kidney or heart transplant recipients. Antibodies directed
against endothelial antigens or stress-induced antigens, such as
vimentin, collagen V, Kα1 tubulin, AT1R, and MICA have also
been reported in transplant recipients but the role of these non-
HLA antibodies in the destruction and accelerated dysfunction
of lung allograft remains poorly addressed (60). These reports
have nevertheless raised interest in chronic injury resulting
from humoral responses targeting non-HLA antigens, as these
may be underestimated by the standard monitoring of patients’
immunization status which is mainly restricted to the detection
of anti-HLA alloantibodies (52). While the rate of acute rejection
during the first year was previously identified as a risk factor
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FIGURE 5 | Kaplan-Meir survival analysis of lung allograft survival stratified
according to FCGR2A [131R/H] genotypes. The FCGR2A [131R/R]
homozygous genotype (solid black line, n = 39) is associated with lower
survival rates in LTRs when compared to FCGR2A [131H/R] (gray line, n = 68)
or the FCGR2A [131H/H] (dashed line, n = 51).
for CLAD occurrence, occurrence of acute rejection in the first
trimester could not be associated with an enhanced risk of
developing chronic rejection nor with patient or graft survival
in the present cohort. The F allelic variant of CD16 with low
affinity for the Fc fragment of IgG was associated with the early
development during the first month post-LTx of DSA that persist
at M3. Persistence of DSA at M3 was thus less frequent in
FCGR3A [158V/V] LTRs and was shown to be associated with
lower survival times in LTR.
Our observations also identify a link between the presence
of circulating DSA at M3 and the FCGR2A [131R/R] genotype,
thus suggesting that FCGR2 polymorphisms may actually be
associated with the persistence of harmful DSA at M3 rather than
in the development of anti-HLA antibodies per se. The FCGR2A
[131R/R] genotype was reported to be associated with shorter
allograft survival in immunized kidney transplant recipients
(KTR) (61, 62). We find that, independently of the risk associated
with the FCGR2A [131R/R] genotype, detection and persistence
of DSA at M3 constitute independent predictors of the adverse
clinical composite outcome comprising CLAD or the patient’s
death. The persistence of DSA has been reported as a risk factor
linked to BOS and to LTR death (16). A recent report showed that
a majority of patients who were positive for de novo DSA during
the first year after LTx developed BOS and were at higher risk of
graft failure or death (63). In line with these reports, our study
suggests that, independently of the presence of the susceptible
FCGR2A [131R/R] genotype, the presence at M1 of DSA with
high affinity for donor antigens (MFI DSA M1 > 18,750) can be
identified as a risk factor associated with lower survival of LTRs.
The role of the complement-dependent pathogenicity of DSA
is less well-documented in the lung transplant setting (19, 20). In
a murine model of BOS, complement activation by antibodies to
HLA class I was not required for the development of obliterative
airway disease (OAD) that is similar to BOS in human LTx.
Interestingly, in this study, at 90 days after LTx, only one out of
5 BOS patients had C1q DSA detected by SAFB whereas 3 out of
11 stable patients had C1q DSA. However, in our study, C1q DSA
detected at M1 andM3 were mostly directed against HLA class II
antigenic targets (90%) and do not appear as major contributors
associated with the development of CLAD.
Although this is a limitation of the study, we cannot exclude
the idea that auto-antibodies that target non-HLA antigens
which were associated with the development of DSA, such
as autoantibodies against K-α1 tubulin (K-α1T) and collagen
V (ColV) (64), can participate in the chronic FcR-dependent
reaction of recipient cells toward the lung allograft. This is
supported by studies that report that development of col (V)-
specific TH-17 cells may contribute to the pathogenesis of BOS
(25, 59). Indeed, our standardized NK-CHAT evaluation of the
DSA induced NK-cell activation was conducted toward B cell
lines that express cognate HLA alloantigens. As B cells may
not be relevant to evaluate the deleterious impact of non-HLA
alloantibodies toward the lung allograft, this is a limit that
prompts further studies that uses serum-coated lung epithelial or
endothelial cells targets to evaluate NK cell ADCC.
FCGR2A [131R/H] is considered to be a heritable risk factor
for a variety of infectious and inflammatory autoimmune
diseases, including systemic lupus erythematosus, rheumatoid
arthritis, malaria, multiple sclerosis, and anti-neutrophil
cytoplasmic auto-antibody positive systemic vasculitis (65).
The CD32 membrane receptor is expressed by a variety of
immune cells that orchestrate the humoral immune response
to pathogens, including B-lymphocytes, natural killer cells,
macrophages, mast cells, and neutrophils. Its capacity to
recognize IgGs bound to pathogens or infected cells has a
protective effect against infections. While the FCGR2A allelic
isoforms exhibit similar affinity for IgG1, the FCGR2A [131H/H]
is the only FcγR variant that recognizes IgG2 subclasses, thus
suggesting that the capacity to sense IgG2 antibodies may
lead to impairment of pathogen surveillance in patients that
lack the H allele. This SNP has been shown to play a role in
the susceptibility to bacterial infections as FCGR2A [131H/H]
individuals have greater potential to mediate IgG2-dependent
bacterial phagocytosis than patients genotyped as FCGR2A
[131R/R]. A distinct SNP (rs12746613) within the FCGR2A
gene was previously associated with a higher risk of respiratory
infections and mortality after LTx, but this variant was not
associated with the risk of developing CLAD (34). Unlike other
studies, our analysis of the present LTR cohort did not reveal
any significant association between FCGR2A [131R/H] and
occurrence of respiratory infections or the number of infection-
related deaths. This discrepancy may relate to preventive and
curative treatment of bacterial infections that differ between the
transplantation centers. It may also reflect a complex interaction
of these FCGR genotypes that encourages the overall survival of
LTR for patients that have better capacities to thwart infections
and overcome early acute rejection events. The observed finding
of a inverse link between the FCGR2A [131R/R] susceptibility
genotype and presence of the FCGR3A-V allele encoding the
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TABLE 6 | Univariate analysis and multivariate Cox regression analysis of variables associated with graft loss and patient death post-LTx.
Covariables Univariate
analysis p-value
Hazard ratio Std. Err. z P>z (95% Conf.interval)
Death, All causes, n = 64
FCGR2A [131R/R] 0.114 1.8 0.511 1.99 0.047 1.008 – 3.121
Native Lung Disease: Cystic Fibrosis 0.048 0.5 0.53 −2.25 0.024 0.278 – 0.915
MFI DSA M1 > 18,750 (75 percentile) 0.109 2.7 1.123 2.36 0.018 1.184 – 6.093
Graft loss or LTR death, n = 68
FCGR2A [131R/R] 0.052 1.85 0.552 1.99 0.047 1.008 – 3.392
MFI DSA M1 > 18,750 (75 percentile) 0.166 2.8 1.259 2.29 0.022 1.159 – 6.759
RAS 0.009 2.8 1.385 2.08 0.037 1.062 – 7.384
Native Lung Disease: Cystic Fibrosis 0.034 0.53 0.181 −1.86 0.063 0.272 – 1.034
DSA at M1 persisting at M3 0.153 1.37 0.550 0.78 0.436 0.622 – 3.009
Bilateral Lung Transplant 0.161 0.92 0.319 −0.24 0.814 0.467 – 1.818
Covariables (risk covariables) used to explain the Lung transplant outcome primary variable (Death all cause or Graft loss/death) are listed on the left column. The bold text refers to
covariables that retained independent significant p-values in multivariate cox regression models.
CD16 receptor variant with higher affinity for the IgG Fc
fragment in LTRs, may in part explain a lack of association
of the FcCR3A-VV genotype with DSA- mediated chronic
lung allograft dysfunction. In this study, the presence of the
FCGR2A [131H/H] was observed to be strongly associated with
the presence of the “high IgG1 responder” FCGR3A [158V/V]
genotype, and such linkage disequilibrium may in part explain
how this intricate distribution of susceptible and protective FCR
SNPs may participate in the complex tuning of the host immune
response to early infectious and humoral challenges and may
be associated with enhanced survival and lower rates of CLAD
in patients who have the protective FCGR2A [131H/R or H/H]
genotype, notably in female LTRs.
In addition to this protective role against pathogens, the
SNP dependent affinity of CD32 for the Fc fragment of
IgG and/or CRP ligands was also identified as promoting
inflammation. CD32-dependent triggering of immune cells is
in part conditioned by the polymorphism and the expression
profile of this functional receptor at the surface of immune
cells. As is expressed by most leukocytes/macrophages that
infiltrate the lung graft, FCGR2A [131R/H] could also influence
the acquisition of an inflammatory-activated profile that favors
tissue recruitment of activated lymphocytes to the lung
(66). Interestingly, the FCGR2A [131R/R] susceptible genotype
identified in this study has been associated with higher CRP
binding avidity for the CD32 receptor expressed at the surface
of monocytes and neutrophils.
Considering the growing evidence of the key role of CRP
as an inflammatory mediator involved in the development
of atherosclerosis and endothelial dysfunction, it is expected
that CRP may be more powerful in triggering the pro-
inflammatory function of CD32-expressing cell subsets such as
platelets, endothelial cells, monocytes, and leukocytes in FCGR2A
[131R/R] LTRs.
In conclusion, these data highlight that FCGR2A and
FCGR3A polymorphisms constitute predisposing factors that
are associated with the outcome of lung allografts. This study
suggests that the combined assessment of the FCGR genotype
and CRP or IgG ligands is thus an intriguing prospect to further
decipher the complex mechanisms that shape the alloimmune
and inflammatory responses in response to infectious and
humoral threats. As shown in other organ transplant settings, our
study indicates FCGR genotyping may favor early stratification
of patients at risk and may create new perspectives to adapt
personalized preventive and therapeutic approaches to prevent
adverse outcomes of lung transplants.
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